Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPRAFII, HanadiRUGGERI, AnnalisaKENZEY, ChantalSANZ, JaimeTOUR, Regis Peffault De laESQUIROL, AlbertMICHEL, GerardCHEVALLIER, PatriceRUBIO, Marie-ThereseCORNELISSEN, Jan J.MICHALLET, MauricetteVOLT, FernandaRIVERA-FRANCO, Monica M.SCIGLIUOLO, Graziana MariaCAPPELLI, BarbaraROCHA, VandersonGLUCKMAN, Eliane2023-08-162023-08-162023BLOOD ADVANCES, v.7, n.10, p.1976-1986, 20232473-9529https://observatorio.fm.usp.br/handle/OPI/54596Subsequent neoplasms (SNs) compromise long-term survivors after hematopoietic cell transplantation. We performed a retrospective analysis of SNs in 10 358 recipients of umbilical cord blood transplantation (UCBT) from 1988 to 2018. SNs developed in 233 patients and 84 were of pediatric age. Indications for UCBT were malignant hematological diseases in 199 patients (85%). Three groups of SNs were observed. Posttransplant lymphoproliferative disorders (PTLD) were reported in 145 patients in a median of 4 months after UCBT. Of these, 9 patients died from relapse, 83 from PTLD, and 24 from transplant-related causes. At last follow-up, 29 were alive; 5-year overall survival (OS) after PTLD diagnosis was 21%. Acute leukemia/myelodysplasia (AL/MDS) was diagnosed in 23 patients in a median of 28 months after UCBT and included 3 donor-cell AL. Four of 23 patients died from relapse of primary disease, 8 from progression of SNs, and 4 from TRM. Seven patients remain alive; the 5-year OS after AL/MDS diagnosis was 36%. Solid tumors (ST) were reported in 65 patients in a median of 54 months after UCBT. Most common tumor sites were lung, thyroid, bone, and soft tissue. A total of 33 patients died (26 owing to ST, 6 to relapse of primary disease, and 1 cause missing). At last follow-up, 32 of 65 patients were alive; the 5-year OS after the diagnosis of ST was 51%. In conclusion, despite their poor outcomes, SNs that occur after UCBT are extremely rare. Identification of risk factors and early detection may help to improve OS.engopenAccessstem-cell transplantationacute myeloid-leukemiaposttransplant lymphoproliferative disorder2nd solid cancersebv reactivationrisk-factorsmarrow-transplantationbone-marrowhematologic malignanciesmyelodysplastic syndromearticleCopyright ELSEVIER10.1182/bloodadvances.2022007941Hematology2473-9537